Siemens is planning to list its 40 billion euro ($47.94 billion) healthcare unit Healthineers in March, two people close to the matter said, as the group hopes to execute the deal while market conditions are favourable.
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. The tailor-made vaccines, given to three patients with advanced melanoma, appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors. The finding is a boost to cancer immunotherapy, a treatment strategy that unleashes the immune system to seek out and destroy cancer. The research is reported April 2 in Science Express, in a special issue devoted to cancer immunology and immunotherapy.